|
SAM-e for the Treatment of Depression in Patients with Parkinson's Disease Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about SAM-e for the Treatment of Depression in Patients with Parkinson's Disease conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. SAM-e for the Treatment of Depression in Patients with Parkinson's Disease Clinical research trials and SAM-e for the Treatment of Depression in Patients with Parkinson's Disease health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including SAM-e for the Treatment of Depression in Patients with Parkinson's Disease. SAM-e for the Treatment of Depression in Patients with Parkinson's Disease Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a SAM-e for the Treatment of Depression in Patients with Parkinson's Disease clinical trial. Human subjects often get the best healthcare possible for their SAM-e for the Treatment of Depression in Patients with Parkinson's Disease condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SAM-e for the Treatment of Depression in Patients with Parkinson's Disease  SAM-e for the Treatment of Depression in Patients with Parkinson's Disease
SAM-e for the Treatment of Depression in Patients with Parkinson's Disease
For Condition: Parkinson's Disease,Depression
Status: Recruiting
Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) , Office of Dietary Supplements (ODS)
Synopsis: This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
Details: PD is commonly associated with depression, but conventional antidepressants have limited efficacy in patients with PD and may exacerbate motor symptoms. SAM-e is available in the United States as a food supplement and is promoted as a mood enhancer. SAM-e improves dopamine transmission, may have a beneficial effect on dopamine receptors, and may be a good alternative to the currently-used antidepressants in patients with PD. This study will investigate whether SAM-e is safe and effective in the treatment of depression associated with PD. The efficacy of SAM-e will be compared to placebo and to escitalopram, a selective serotonin reuptake inhibitor commonly used for the treatment of depression in PD. Participants in this study will be randomly assigned to receive SAM-e, escitalopram, or placebo for 12 weeks. Some participants may choose to extend treatment for an additional 12 weeks (for a total of 24 weeks on study medication). Participants will have study visits at entry and Weeks 2, 4, 8, and 12. Study visits will include neurological evaluation, psychiatric evaluation, blood tests, and quality of life questionnaires. A telephone interview will be conducted at Week 10.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 30 Years/80 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Idiopathic Parkinson's disease as indicated by the presence of at least two of the following signs: resting tremor, rigidity, bradykinesia, or postural reflex impairment - Stable anti-parkinson medication regimen, with no change in medications in the 4 weeks prior to study entry - No antidepressant or antipsychotic medications within 30 days prior to study entry - Agree not to start other pharmacotherapy, psychotherapy, or behavior therapy while participating in the trial - Acceptable methods of contraception - Ability to read and/or follow written and oral instructions presented in English - Sufficient cognitive ability (baseline Mini-Mental Status > 24) to provide informed consent Exclusion Criteria - History of cardiac, hepatic, renal, hematologic, respiratory, endocrine, vascular, metabolic, or other systems abnormalities that are clinically relevant in the opinion of study officials - Certain abnormal laboratory values - Pregnant or breastfeeding - Use of an investigational drug within 3 months of study entry - Use of St. John’s Wort or any other “natural” product known to have mood enhancing properties in the 30 days prior to study entry - Selegiline or other monoamine oxidase inhibitor within the 6 weeks prior to study entry - Regular usage of anti-anxiety medications or habitual use of sleep medications, although occasional use of certain hypnotics (temazapam, melatonin, or zolpidem) is allowed - Psychotherapy initiated in the 6 months prior to study entry - History of bipolar disorder, hypomania, mania, schizophrenia, or other psychotic disorder - Serious suicidal attempt in the 12 months prior to study entry or serious suicidal tendencies/potential - Use of dopamine receptor antagonist (metoclopramide, haloperildol) - Secondary Parkinsonian symptoms due to drugs (including dopamine receptor antagonists), metabolic disorders, cerebrovascular disease, encephalitis, or other degenerative diseases
Total Enrollment: 100
Location and Contact Information:
Overall Study Official:
AlessandroRocco, Principal Investigator, Beth Israel Medical Center
Beth Israel Medical Center *Recruiting*
New York City, New York, 10003
United States
Recruiting Milana Veytsman 212-844-8718
Additional Information:
Study ID Numbers: 1 R01 AT00941-01A1;
Study Start Date: July 2003
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00070941
Other Depression Studies:
1. Magnetic Stimulation for Parkinson Disease
2. Parkinson's disease treatment with coenzyme Q10
3. Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial
4. KW-6002 to Treat Parkinson's Disease
5. Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
Related Studies:
Other Depression Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
SAM-e for the Treatment of Depression in Patients with Parkinson's Disease
|
|
|
|
|
|
|
|
